After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene (CELG) or Gilead (GILD) .

Cramer addressed these stocks on Thursday's edition of CNBC's Mad Money.

Meanwhile, President Trump is set to deliver a speech on drug pricing on Friday. 

For exclusive investing insight from Jim Cramer, get 24/7 access to Jim's charitable trust portfolio with a free trial to Action Alerts PLUS!

More from Video

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

Watch: Here's What Wall Street Is Tracking Monday as Trump Sends Stocks Lower

Watch: Here's What Wall Street Is Tracking Monday as Trump Sends Stocks Lower

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False

This Cannabis Beverage Company Is Staying Away From the United States

This Cannabis Beverage Company Is Staying Away From the United States

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

Video: 2018 Is Actually a Normal Year for Stock Market Volatility